Objective: To present a good tacrolimus (FK506) administration protocol in liver transplantation.
Methods: Fifty liver transplantation patients were classified into FK506 high-concentration (20 patients), FK506 mid-concentration (20), CsA-FK506 (5) and FK506-CsA (5) groups. Clinical manifestations, FK506 side-effects and pathological changes were observed.
Results: The FK506 high-concentration group showed complications such as infection and liver function damage. The FK506 mid-concentration group showed excellent therapeutic results and some complications easy to deal with.
Conclusion: FK506 is a highly effective immunosuppressive agent and the mid-concentration protocol is a better one.